Evidence map›Paper›PMID 38348622›Full record

ArticleHuman vaccines & immunotherapeutics2024

Exploration of genetic characterization in hyperprogressive disease after immunotherapy retreatment in a patient with LCNEC: A case report.

Yao Zhang, Jiayao Yang, Tianyu Shao, Jialu Chen, Qijin Shu, Liumei Shou

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Yao ZhangThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Jiayao YangThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Tianyu ShaoDepartment of Oncology, Guang' Anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Jialu ChenDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, China.
Qijin ShuDepartment of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Liumei ShouDepartment of Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.ORCID 0000-0002-9339-8454
Zhejiang Chinese Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNThird People's Hospital of Hangzhou · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic option for large cell neuroendocrine carcinoma (LCNEC). However, various studies have suggested a potential risk of hyperprogressive disease (HPD) in patients receiving ICI, which might be associated with gene alterations. Here, this is the first report on an unknown primary LCNEC patient who had achieved a long-term response from ICI treatment (atezolizumab), but developed HPD after tumor progression due to receiving another ICI agent (serplulimab). The mutation region of FAT4, SMARCA4, CYLD, CTNNB1, and KIT was altered prior to serplulimab treatment compared to before atezolizumab treatment. This case suggested a potential association between these mutated genes and HPD. Patients with the aforementioned genes should caution when selecting ICI treatment. These findings required further confirmation in a larger study cohort.

Indexed as

Carcinoma, NeuroendocrineImmune Checkpoint InhibitorsAntibodies, MonoclonalDisease ProgressionDNA HelicasesHumansImmunotherapyNuclear ProteinsRetreatmentTranscription FactorsAntibodies, MonoclonalDNA HelicasesImmune Checkpoint InhibitorsNuclear ProteinsSMARCA4 protein, humanTranscription Factorsgenetic characterizationhyperprogressive disease (HPD)immune checkpoint inhibitors (ICIs)Large cell neuroendocrine carcinoma (LCNEC)retreatment with immunotherapy

Identifiers

PMID38348622
PMCPMC10865920
OpenAlexW4391781332

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.